ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
| | | |

ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19

On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…

OpGen subsidiary Ares Genetics demonstrated feasibility and next generation sequencing based antibiotic susceptibility testing in multi-center study
| | | |

OpGen subsidiary Ares Genetics demonstrated feasibility and next generation sequencing based antibiotic susceptibility testing in multi-center study

On Apr. 16, 2020, OpGen announced that a study on the feasibility and potential of antibiotic susceptibility testing…